

# Limited induction of lung-resident memory T cell responses against SARS-CoV-2 by mRNA vaccination

Daan K.J. Pieren<sup>1</sup>, Sebastián G. Kuguel<sup>1</sup>, Joel Rosado<sup>2</sup>, Alba G. Robles<sup>1</sup>, Joan Rey-Cano<sup>1</sup>, Cristina Mancebo<sup>1</sup>, Juliana Esperalba<sup>4</sup>, Vicenç Falcó<sup>1</sup>, María J. Buzón<sup>1</sup>, Meritxell Genescà<sup>1\*</sup>

## Affiliations

<sup>1</sup>Infectious Diseases Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain;

<sup>2</sup>Thoracic Surgery and Lung Transplantation Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain;

<sup>3</sup>Respiratory Viruses Unit, Microbiology Department, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Passeig Vall d'Hebron 119-129, 08035 Barcelona, Spain.

\*Correspondence: [meritxell.genesca@vhir.org](mailto:meritxell.genesca@vhir.org) (M.G.)

1 **SUMMARY**

2 Resident memory T cells ( $T_{RM}$ ) present at the respiratory tract may be essential to enhance early  
3 SARS-CoV-2 viral clearance, thus limiting viral infection and disease. While long-term antigen  
4 (Ag)-specific  $T_{RM}$  are detectable beyond 11 months in the lung of convalescent COVID-19 patients  
5 after mild and severe infection<sup>1</sup>, it is unknown if mRNA vaccination encoding for the SARS-CoV-  
6 2 S-protein can induce this frontline protection. We found that the frequency of  $CD4^+$  T cells  
7 secreting interferon ( $IFN$ ) $\gamma$  in response to S-peptides was similar in the lung of mRNA-vaccinated  
8 patients compared to convalescent-infected patients. However, in vaccinated patients, lung  
9 responses presented less frequently a  $T_{RM}$  phenotype compared to convalescent infected  
10 individuals and polyfunctional  $T_{RM}$  were virtually absent. Thus, a robust and wide  $T_{RM}$  response  
11 established in convalescent-infected individuals may be advantageous in limiting disease if the  
12 virus is not block by initial mechanisms of protection, such as neutralization. Still, mRNA vaccines  
13 can induce modest responses within the lung parenchyma potentially contributing to the overall  
14 disease control.

15  
16

1 **MAIN**

2 The COVID-19 pandemic continues, and many countries face multiple resurgences. While  
3 vaccines to limit SARS-CoV-2 infection rapidly emerged providing high protection from COVID-  
4 19, more insight into the mechanisms of protection induced by available vaccines is still needed.  
5 The level of vaccine-induced neutralizing antibodies has been shown to correlate with protection  
6 from symptomatic infection; however, predicted antibody-mediated vaccine efficacy declines over  
7 time<sup>2</sup>. Moreover, many viral variants of concern (VOC) can significantly evade humoral immunity,  
8 yet cellular responses induced by vaccines show strong cross-protection against these variants<sup>3</sup>,  
9 <sup>4</sup>, supporting the idea that cellular responses largely contribute to disease control<sup>5</sup>. In fact,  
10 preexisting cross-reactive memory T cells and early Nucleocapsid (N) responses against  
11 coronaviruses are associated with protection from SARS-CoV-2 infection<sup>6, 7</sup>. Further, SARS-CoV-  
12 2 infection induces robust cellular immunity detectable beyond 10 months after infection in  
13 peripheral blood<sup>8</sup>, and as T<sub>RM</sub> in the lung<sup>1</sup>, and the number of SARS-CoV-2-specific T<sub>RM</sub> in the  
14 lung correlates with clinical protection<sup>9</sup>. Vaccination against SARS-CoV-2 using BTN162b2  
15 (Pfizer/BioNTech) and mRNA-1273 (Moderna) vaccines has been reported to induce CD4<sup>+</sup> and  
16 CD8<sup>+</sup> T-cell responses in peripheral blood<sup>10, 11</sup>. Moreover, the IFN $\gamma$  T-cell response to SARS-CoV-  
17 2 S-peptides, one of the main antiviral factors measured as a readout, further increased after  
18 boosting<sup>11</sup>. However, current studies only address vaccine-induced SARS-CoV-2 specific T-cell  
19 responses in peripheral blood and whether mRNA vaccines also elicit SARS-CoV-2-specific long-  
20 term T<sub>RM</sub> cells in the lung remains to be established.

21 To this end, we determined the presence of SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells  
22 in 26 paired peripheral blood and lung cross-sectional samples from: I.) uninfected unvaccinated  
23 individuals (Ctrl, n=5), II.) unvaccinated long-term SARS-CoV-2 convalescent individuals (Inf,  
24 n=9, convalescent for a median of 304 days [183-320 IQR]), III.) uninfected and long-term two-  
25 dose vaccinated individuals (Vx2, n=7, a median of 206 days [184-234] after the second dose),  
26 and IV.) uninfected and short-term three-dose vaccinated individuals (Vx3, n=5, a median of 52  
27 days [42-54] after the third dose or boost). Patient characteristics are summarized in Extended  
28 Table 1. In order to confirm the SARS-CoV-2 status of each patient, we analyzed total  
29 immunoglobulin (Ig) or IgG levels against N and Spike (S) proteins respectively, which  
30 discriminated Ctrl (negative for N and S), Inf patients (positive for N and S) and vaccinated groups  
31 (negative for N and positive for S; Extended Table 1). Furthermore, the viral neutralization titer  
32 was determined against the SARS-CoV-2 Omicron variant using a pseudovirus neutralization  
33 assay and, as expected<sup>10, 11</sup>, a positive correlation between neutralization and S-IgG titers was  
34 detected (Spearman  $r = 0.72$ ,  $P = 0.0016$ ; Extended Data Fig.1a). In addition to the absence of

1 neutralization of the Omicron variant in plasma of the Ctrl group, 2 out of 7 patients (28%) in the  
2 Inf group and from 1 out of 6 patients (17%) in the Vx2 group failed to neutralize the virus, whereas  
3 all patients in the Vx3 group were able to neutralize this variant (Extended Table 1). The fact that  
4 we mostly studied elderly patients could certainly determine the overall response and, indeed  
5 there was a negative correlation between older age and neutralizing capacity for the Inf group  
6 (Spearman  $r = -0.88$ ,  $P = 0.01$ ; Extended Data Fig.1b) and the same trend was observed for the  
7 Vx2 group (Spearman  $r = -0.72$ ,  $P = 0.10$ ; Extended Data Fig.1c). This relationship was less  
8 evident between age and S-IgG titers (Extended Data Figs.1d, e), yet examples in larger cohorts  
9 exist<sup>10</sup>. Instead, S-IgG titers from all groups negatively correlated with sample timing (Spearman  
10  $r = -0.61$ ,  $P = 0.010$ ; Extended Data Fig.1f), a correlation that was also observed for total Ig against  
11 N in the Inf group (Spearman  $r = -0.88$ ,  $P = 0.009$ ; Extended Data Fig.1g), which agrees with  
12 antibody titers decay<sup>10, 11, 12</sup>.

13 To address cellular immune responses, we stimulated fresh peripheral blood mononuclear  
14 cells (PBMC) and lung-derived cellular suspensions with overlapping Membrane (M), N and S  
15 peptide pools and determined the intracellular expression of IFN $\gamma$ , interleukin (IL)-4, and IL-10,  
16 along with the degranulation marker CD107a in CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Extended Data Fig.2a),  
17 as previously described<sup>1</sup>. We found detectable circulating IFN $\gamma$ -secreting Ag-specific CD4<sup>+</sup> T cells  
18 responding to all proteins in the blood of Inf patients, which was significantly higher compared to  
19 the Ctrl, Vx2, and Vx3 groups for M and N peptides (Fig. 1a, b). In contrast, for S peptides, the Inf  
20 group only showed higher frequencies of IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cells compared to the Ctrl group, indicating  
21 an increase induced by vaccination in the blood of Vx2 and Vx3 groups. However, only two Vx2  
22 patients showed detectable frequencies of S-specific CD4<sup>+</sup> T cells in blood, while recently boosted  
23 Vx3 patients displayed an overall increase reaching statistical significance compared to the Ctrl  
24 group (Fig. 1b). In contrast to CD4<sup>+</sup> T cells, the frequencies of IFN $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells detected were  
25 minimal for each of the groups against any of the proteins, including for the Vx groups against S  
26 peptides (Fig. 1b). Expression of IL-4, IL-10, and CD107a by T cells showed, in general, high  
27 variability, limiting the detection of differences (Extended Data Fig. 3). Nonetheless, S-specific  
28 degranulating CD107a<sup>+</sup> CD8<sup>+</sup> T cells were overall more frequent in the Vx2 compared to the Ctrl  
29 group ( $P = 0.046$ ; Extended Data Fig. 3). Together, these data indicate that M, N, and S-peptide  
30 specific IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cell responses can be readily detected in blood months after resolving  
31 natural SARS-CoV-2 infection and that these responses require a recent mRNA vaccine booster-  
32 dose against SARS-CoV-2 to elicit similar frequencies against the S protein in vaccinated  
33 individuals.

1 As reported previously<sup>1</sup>, we here found that mild or severe natural infection with SARS-  
2 CoV-2 induced robust IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cells in the lung against M, N, and S peptides, detectable for  
3 up to 12 months after infection (Fig. 2a, b). Interestingly, whereas M and N-specific IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup>  
4 T-cell frequencies were significantly higher in the Inf group compared to Ctrl or Vx groups, these  
5 differences were not observed for S-specific responses (Figs. 2a, b). Vx2 and Vx3 groups showed  
6 presence of S-specific IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cells in the lung in most patients and its frequency was  
7 comparable to levels detected in Inf patients, although statistical significance was not reached  
8 compared to the Ctrl group (Fig. 2b). In contrast to CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells producing IFN $\gamma$  after  
9 stimulation with M, N, or S peptides was variable within each group and did not result in significant  
10 differences between the groups, indicating that natural infection nor vaccination elicit a robust  
11 IFN $\gamma$  positive CD8<sup>+</sup> T cell response in the human lung (Fig. 2b). Furthermore, induction of lung  
12 anti-SARS-CoV-2-specific T-cell responses involving expression of IL-4, IL-10, and CD107a did  
13 not differ between groups (Extended Data Fig. 4a). Of note, in this tissue compartment, we  
14 detected negative correlations between patient's age within the Inf group and the frequency of S-  
15 specific degranulating CD4<sup>+</sup> and CD8<sup>+</sup> T cells (Spearman  $r = -0.76$ ,  $P = 0.024$  and Spearman  $r =$   
16  $-0.77$ ,  $P = 0.020$  respectively, Extended Data Fig. 4b).

17 When we compared the magnitude of S-specific T cells in paired blood and lung samples,  
18 we found increased frequencies of IFN $\gamma$ <sup>+</sup> CD4<sup>+</sup> T cells in the lungs of patients from the Inf group  
19 compared to blood ( $P = 0.039$ , Fig. 2c). The same trend was observed for the Vx individuals, which  
20 was close to significant if both groups were pooled ( $P = 0.054$ ). In contrast, the CD8<sup>+</sup> T-cell  
21 compartment did not show clear differences between these two compartments (Fig. 2c), neither  
22 any of the T-cell subsets for any other function, which were highly variable (Extended Data Fig.  
23 5). Together our data shows that S-specific CD4<sup>+</sup> T-cell responses are detectable in the lung of  
24 uninfected vaccinated patients, indicating that mRNA vaccination against SARS-CoV-2 may elicit  
25 tissue-localized protective T-cell responses already after the second mRNA vaccine dose.

26 Considering the presence of T<sub>RM</sub> in the respiratory tract might provide a better correlate of  
27 protection from disease in SARS-CoV-2 infected individuals<sup>1,9</sup>, we next analyzed expression of  
28 CD69 and CD103 by lung SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells, which we classified as:  
29 CD69<sup>-</sup> (non-T<sub>RM</sub>), CD69<sup>+</sup> (T<sub>RM</sub>) and a subset within CD69<sup>+</sup> cells expressing CD103<sup>+</sup> (T<sub>RM</sub> CD103<sup>+</sup>)  
30 (Fig. 3a, Extended Data Fig. 2b for gating strategy). Of note, CD69<sup>+</sup> T cells showed down-  
31 regulation of T-bet in all groups (Extended Data Fig. 2b), which has been associated to tissue  
32 residency<sup>1</sup>. S-specific CD4<sup>+</sup> T cells from the Inf group showed higher frequencies of IFN $\gamma$ <sup>+</sup> cells  
33 within the CD69<sup>+</sup> and CD103<sup>+</sup> T<sub>RM</sub> phenotypes (Fig. 3a, b), with statistical significance reached  
34 for the overall CD69<sup>+</sup> T<sub>RM</sub> fraction compared to the non-T<sub>RM</sub> fraction. Furthermore, while no

1 significant differences were detected for CD103<sup>+</sup> T<sub>RM</sub> cells against S-peptides in any of the groups,  
2 a trend was observed for CD4<sup>+</sup> T-cell responses to M peptides and statistical significance was  
3 reached for CD8<sup>+</sup> T cells against N peptides compared to the non-T<sub>RM</sub> fraction in the Inf group  
4 (Extended Data Fig. 6a, b). Of note, a negative correlation was observed between IFN $\gamma$ -secreting  
5 S-specific CD8<sup>+</sup> CD103<sup>+</sup> T<sub>RM</sub> cells and sample timing (Spearman  $r = -0.82$ ,  $P = 0.019$  Extended  
6 Data Fig. 6c). Similar to the Inf group, some patients in the Vx2 and Vx3 groups showed presence  
7 of S-specific T<sub>RM</sub> with or without CD103 expression in their lungs (Figs. 3a, b). However, this  
8 response was highly heterogeneous and not statistically significant. These findings indicate that  
9 mRNA vaccination against SARS-CoV-2 can induce S-specific T<sub>RM</sub> in some, but not all individuals  
10 and may also last long term after the second vaccination.

11 To better gain insight into the overall S-specific response by each group, including all  
12 functions and considering lung-T<sub>RM</sub> phenotypes, we represented S-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cell  
13 subsets as donut charts displaying the mean frequency of responses including all individuals  
14 (responders and non-responders, Fig. 4, b). This way, a dominance of IFN $\gamma$ -secreting CD4<sup>+</sup> T  
15 cells was particularly associated to the two T<sub>RM</sub> phenotypes in the Inf and, to a lesser extent, in  
16 the Vx2 patients (Fig. 4a). Further, S-specific responses within non-T<sub>RM</sub> and blood CD4<sup>+</sup> T cells  
17 were functionally similar and in general dominated by IFN $\gamma$  and IL-4 secretion (Fig. 4a). In  
18 contrast, degranulation characterized the majority of lung S-specific CD8<sup>+</sup> T cells from Inf  
19 individuals (Fig. 4b), which correlated negatively with older age for the T<sub>RM</sub> fractions (Spearman  $r$   
20  $= -0.88$ ,  $P = 0.006$  for both CD103 positive and negative, Extended Data Fig. 6d). Degranulation  
21 was also the major function in blood from the two Vx groups (Fig. 4b). Last, in general, CD8<sup>+</sup> T-  
22 cell responses considering all functions were of higher magnitude in long-term Vx2 individuals,  
23 reaching statistical significance for blood responses in comparison to the Ctrl group, as shown in  
24 the adjoin graph on the right (Fig. 4b).

25 We previously detected a low but consistent polyfunctional IFN $\gamma$ <sup>+</sup>CD107a<sup>+</sup> T-cell response  
26 mostly associated to the T<sub>RM</sub> fraction in convalescent infected patients<sup>1</sup>. We therefore investigated  
27 whether mRNA vaccination against SARS-CoV-2 would also induce S-specific polyfunctional  
28 responses in both compartments (Figs. 5a, b). Indeed, increased frequencies of polyfunctional  
29 IFN $\gamma$ <sup>+</sup>CD107a<sup>+</sup> CD4<sup>+</sup> T cells were detected in blood from the Inf group against N peptides  
30 compared to the Ctrl group, but not against M- and S-peptides. Interestingly, a trend towards  
31 higher frequencies of S-specific polyfunctional CD4<sup>+</sup> T cells was observed for the Vx3 group (Fig.  
32 5a). Likewise, circulating polyfunctional S-specific CD8<sup>+</sup> T cells were enhanced in Vx2 individuals  
33 compared to Ctrl group (Fig. 5a). In fact, if Vx groups were pooled to increase sample size, then  
34 both CD4<sup>+</sup> and CD8<sup>+</sup> T cells reached significance compared to Ctrl samples ( $P = 0.037$  for CD4<sup>+</sup>

1 and  $P = 0.024$  for CD8<sup>+</sup>). In addition, the frequency of polyfunctional IFN $\gamma$ <sup>+</sup>CD107a<sup>+</sup> cells present  
2 in total CD4<sup>+</sup> and CD8<sup>+</sup> T cells in the lung were only consistently increased in the Inf group against  
3 N peptides compared to the Ctrl and Vx3 groups (Fig. 5b). Nevertheless, while a high degree of  
4 variability was observed among vaccinated patients, polyfunctional S-specific T cells were  
5 detected in some individuals (Fig. 5b). Strikingly, S-specific CD4<sup>+</sup> polyfunctional CD103<sup>+</sup> T<sub>RM</sub> cells  
6 were virtually absent in the Vx2 and Vx3 groups, while being frequently present in the lungs of  
7 patients from the Inf group (Extended data Fig. 7). Furthermore, the frequency of S-specific  
8 polyfunctional CD4<sup>+</sup> T cells in the CD69<sup>+</sup> T<sub>RM</sub> cells was higher in the Inf group compared to the  
9 Ctrl and Vx2 groups (Extended data Fig. 7). Together, these data indicate that both short- and  
10 long-term vaccination do not induce S-specific IFN $\gamma$ <sup>+</sup>CD107a<sup>+</sup> CD103<sup>+</sup> T<sub>RM</sub> cells in the lung, which  
11 may contribute to antiviral activity.

12 Last, considering the uniqueness of analyzing immune responses in paired blood and lung  
13 parenchyma samples and recent studies detailing changes in T cell responses in infected  
14 individuals already vaccinated and vice versa<sup>13</sup>, we highlight two patients that were discarded due  
15 to not fitting inclusion criteria, yet bring interesting data to the study. HL174 was a patient in their  
16 fifties who received the third mRNA-1273 vaccine boost and, five days after, tested positive by  
17 PCR. We analyzed paired tissue samples 30 days after the boost/infection event (Extended Data  
18 Fig. 8a). This patient had a neutralization titer of 1740 IU/mL against omicron, and had detectable  
19 IgG and Ig titers against S and N proteins (>800 AU/mL and 1.23 index, respectively). When  
20 comparing T-cell responses from blood and lung tissue, a much higher IFN $\gamma$ -response was  
21 observed in the lung, in particular against the N protein, which already contained responding cells  
22 with a T<sub>RM</sub> phenotype (Extended Data Fig. 8b, c). In contrast, in blood, degranulation was  
23 enhanced mostly against S but also M protein and some proportion of IL-10 secretion was  
24 detected against all proteins (Extended Data Fig. 8b).

25 On the other hand, patient HL162, who was in their early seventies, was first infected  
26 presenting a mild COVID-19 and, several months after, received three doses of the mRNA-1273  
27 vaccine. In this case, we obtained samples 3.7 months after infection and another one 1.3 months  
28 after the third dose (due to a second intervention for a lung carcinoma), which corresponded to a  
29 year after initial infection, as shown (Extended Data Fig. 9a). Neither of these two time points  
30 showed neutralization titers against omicron and the titers of IgG, instead of increasing after triple  
31 vaccination, decreased from 156 to 0 index for the N protein and from 306.54 to 13.85 AU/mL for  
32 S protein. The comparison of the tissue compartments after infection and after triple vaccination  
33 evidenced a concomitant strong decrease in T-cell responses in blood and tissue (Extended Data  
34 Figs. 9b, c, and Extended Data Fig. 10a, b). However, IFN $\gamma$ -secreting SARS-CoV-2 T cells against

1 M and N proteins in the lung were better preserved from the original infection one year later than  
2 were responses against the S protein enhanced due to vaccination (Extended Data Fig. 9b, c,  
3 and Extended Data Fig. 10a, b). Thus, while the lower respiratory tract compartment more  
4 faithfully represented  $T_{RM}$  responses established already during the infection event one year  
5 earlier, responses in blood mostly vanished.

6 Comprehensive studies comparing the magnitude and duration of the T cell responses  
7 indicate similar magnitude after dual vaccination and after natural SARS-CoV-2 infection<sup>5, 11, 13</sup>.  
8 However, these results may not hold if we consider that the magnitude, the functional profile and  
9 even the duration of these responses in blood may not faithfully reflect responses in the  
10 respiratory tract<sup>1, 7, 9, 14</sup>. In fact, the individual comparison between these two compartments  
11 among the S-responding T cells from the different groups showed higher magnitude in the lung  
12 than in the blood, but also a different profile. A key difference, and the main driver of our study,  
13 was the establishment of long-term protection potentially mediated by  $T_{RM}$  after vaccination, since  
14 longevity of SARS-CoV-2 T cell responses remains a critical question<sup>7</sup>. In principle,  $T_{RM}$  are  
15 established by mucosal infection since Ag together with local signals promote the recruitment and  
16 establishment of this memory response. In this sense, intramuscular vaccination with an  
17 adenovector vaccine in mice did not induce SARS-CoV-2-specific  $T_{RM}$  in their lungs<sup>15</sup>. Thus, to  
18 induce potent resident immunity, vaccine strategies may need to either use live-attenuated Ag or  
19 employ mucosal routes. Consequently, the absence of vaccine induced S-specific  $T_{RM}$  could be  
20 expected in infection-naïve individuals. Still, recent data shows that a secretory IgA response was  
21 induced in ~30% of participants after two doses of a SARS-CoV-2 mRNA vaccine which, in  
22 addition, may play an important role in protection against infection<sup>14</sup>. While we detected S-specific  
23  $IFN\gamma^+ CD4^+$  T cell responses in the lung of vaccinated individuals, the proportion of these cells in  
24 the  $T_{RM}$  phenotype was modest, in particular if considering CD103 expression. Further, the  
25 presence of polyfunctional  $IFN\gamma^+ CD107a^+ CD4^+ CD103^+ T_{RM}$  appeared to be restricted to the lungs  
26 of convalescent-infected patients only. Yet, lung S-specific  $CD8^+ T_{RM}$  presented similar overall  
27 frequencies in vaccinated individuals when considering all functions. In fact, overall  $CD8^+$  T cell  
28 response, which was in general low and dominated by degranulation, appeared enhanced in  
29 some but not all vaccinated patients. Considering the putative protective role of  $CD8^+$  T cells  
30 observed in animal models<sup>16</sup>, our results for these vaccinated individuals are certainly  
31 encouraging.

32 Another difference in the comparison of the cellular immunity between SARS-CoV-2-  
33 infected convalescent and uninfected-vaccinated individuals is the broader and, potentially  
34 stronger, response induced by symptomatic infection. This is partially manifested by the fact that,



1 when comparing the overall magnitude, responses against M and N peptides are frequently higher  
2 than S peptides<sup>1, 17, 18, 19</sup>. Of note, disease severity may impact both, the magnitude and function  
3 of the T cell response against the different proteins<sup>1, 20, 21</sup>. In addition, among other factors, age  
4 also influences the magnitude and duration of immune responses in distinct tissue compartments,  
5 even the establishment of T<sub>RM</sub><sup>22</sup>, a factor that influenced the frequency of degranulation in the  
6 lung of our Inf patients, including within the T<sub>RM</sub> fraction. Yet advanced age will also limit the  
7 immune response to vaccination<sup>23</sup>. On the other hand, we have observed that different proteins  
8 induce different functional profiles during acute infection, which may influence disease control<sup>1</sup>.  
9 Responses against the N protein seem to more consistently induce polyfunctional antiviral T cells  
10 and these responses may be more conserved among other coronaviruses<sup>1, 6, 24, 25</sup>. Instead, S-  
11 specific immune responses may better support B cell and antibody generation via follicular helper  
12 T cells, instrumental for limiting infection<sup>1, 5</sup>. Thus, another conclusion would be highlighting the  
13 interest of including other proteins beyond the spike such as N sequences, which has been  
14 suggested before<sup>1, 6, 19, 25, 26</sup>. Last, in terms of duration, our study lacks longitudinal data to assess  
15 the dynamics in the different compartments, yet it is assumed that T<sub>RM</sub> phenotypes will contribute  
16 to long-term persistence<sup>1, 7, 16</sup>. In fact, the only patient for which we had longitudinal sampling after  
17 infection and after the third vaccine boost (extended Fig. 9) demonstrated that even if vaccination  
18 fails to induce a systemic antibody response, a low frequency SARS-CoV-2 T cell response  
19 directed to proteins from the original infection remains exclusively detectable in the lung as T<sub>RM</sub>  
20 one year after.

21 We acknowledge that our study has several limitations, including the small sample size  
22 for the different groups. In addition, we addressed T cell immune responses in older and mostly  
23 oncologic patients, which may overall underestimate immune responses in all groups. Whereas  
24 the fact that the Inf group consisted of patients recovered from mild or severe disease, even if  
25 age and underlying conditions were similar to the other groups, may have skewed frequencies of  
26 SARS-CoV-2-specific T cells towards the higher end. Still, considering their age and condition,  
27 any of these patients with a new infection would most likely develop a more serious COVID-19  
28 event compared to the general population. In addition, the boosted Vx3 group was sampled short  
29 term comparing to the Vx2 group, but enhancement of T cell responses would be better detected  
30 5-10 days after boosting<sup>10, 11</sup> (which was a less likely time for scheduling surgery). Still it was  
31 enough to suggest that there was no major enhancement of long-term durable T cell response in  
32 the lung by a third boost. Further, we did not assess the contribution of T cells targeting mutation  
33 regions to the total spike since we aimed to compare the strength and function of vaccinated and  
34 naturally infected patients (these last group obtained during the first wave). However, the overall

1 contribution of T cell responses to mutational regions/total spike responses has been reported to  
2 be low<sup>13, 27</sup>. Last, low percentages of SARS-CoV-2 specific CD8<sup>+</sup> T cells may be due to the use  
3 of 15-mer peptides, which are less optimal than 9/10-mer peptides for HLA class I binding<sup>4</sup>,  
4 although this is debatable<sup>21</sup>.

5 Overall, our results contribute to the understanding of disease protection mediated by  
6 current mRNA vaccines. While our data indicates a more robust and broader cellular response in  
7 convalescent patients, S-specific T cells can be detected in the lung of vaccinated individuals to  
8 similar overall levels 8 months after immunization, highlighting the durability of this immune arm.  
9 Further, while we detected increased levels of IFN $\gamma$ <sup>+</sup> T cell responses in blood after the third dose,  
10 limited benefit of boosting towards the enhancement of T cell responses in the lung was evidenced  
11 by our data. However, elderly people not responding to vaccination have been shown to benefit  
12 from a third dose<sup>23</sup> and there is an obvious benefit of boosting to provide a higher degree of  
13 antibody-mediated protection from infection in the context of high incidence of VOC<sup>2</sup>. Still, if virus  
14 neutralization is unable to completely block infection, a more robust and wider T<sub>RM</sub> response  
15 established in the lung of convalescent-infected individuals may have more chances of limiting  
16 disease. The inclusion of other protein fragments such as nucleocapsid peptides<sup>1, 6, 19, 25, 26</sup> in  
17 combination with mucosal routes<sup>28</sup> will likely contribute to the establishment of optimal memory T  
18 cells in future vaccine strategies.

19

## 20 **METHODS**

### 21 **Ethics statement**

22 This study was performed in accordance with the Declaration of Helsinki and approved by the  
23 corresponding Institutional Review Board (PR(AG)212/2020) of the Vall d'Hebron University  
24 Hospital (HUVH), Barcelona, Spain. Written informed consent was provided by all patients  
25 recruited to this study.

26

### 27 **Subject recruitment and sample collection**

28 Patients undergoing lung resection for various reasons at the HUVH were recruited through the  
29 Thoracic Surgery Service and invited to participate. Initially, a total of 32 patients, from whom  
30 paired blood samples and lung biopsies were collected were assayed. However, based on  
31 vaccination and/or infection status of the recruited patients, 26 (+2: HL174 and HL162) patients  
32 were finally included. Extended data Table 1 summarizes relevant information from included  
33 patients. For all participants, whole blood was collected with EDTA anticoagulant. Plasma was  
34 collected and stored at -80 °C (except for 4 patients distributed among the different groups, as

1 indicated in Extended Data Table 1, for which this sample was not available) and PBMCs were  
2 isolated via Ficoll–Paque separation and processed immediately for stimulation assays.

3

#### 4 **Phenotyping and Intracellular Cytokine Staining of lung biopsies**

5 Immediately following surgery, healthy areas from patients undergoing lung resection were  
6 collected in antibiotic-containing RPMI 1640 medium and processed as published<sup>1</sup>. Briefly, 8-mm<sup>3</sup>  
7 dissected blocks were first enzymatically digested with 5 mg/ml collagenase IV (Gibco) and  
8 100µg/ml of DNase I (Roche) for 30 min at 37 °C and 400 rpm and, then, mechanically digested  
9 with a pestle. The resulting cellular suspension was first filtered through a 70µm pore size cell  
10 strainer and then filtered through a 30µm pore size cell strainer (Labclinics). After washing with  
11 PBS, cells were stimulated in a 96-well round-bottom plate for 16 to 18 hours at 37°C with 1µg/mL  
12 of SARS-CoV-2 peptides (PepTivator SARS-CoV-2 M, N or S, Miltenyi Biotec) in the presence of  
13 3.3µL/mL α-CD28/CD49d (clones L293 and L25), 0.55µL/mL Brefeldin A, 0.385µL/mL Monensin  
14 and 5 µL/100µL anti-CD107a-PE-Cy5 (all from BD Biosciences). For each patient, a negative  
15 control, cells treated with medium, and positive control, cells incubated in the presence of 0.4nM  
16 PMA and 20µM Ionomycin, were included. Next day, cellular suspensions were stained with  
17 Live/Dead Aqua (Invitrogen) and anti-CD103 (FITC, Biolegend), anti-CD69 (PE-CF594, BD  
18 Biosciences), anti-CD40 (APC-Cy7, Biolegend), anti-CD8 (APC, BD Biosciences), anti-CD3  
19 (BV650, BD Biosciences) and anti-CD45 (BV605, BD Biosciences) antibodies. Cells were  
20 subsequently fixed and permeabilized using the FoxP3 Fix/Perm kit (BD Biosciences) and stained  
21 with anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE, BD Biosciences), anti-T-bet (BV421,  
22 Biolegend) and anti-IFN $\gamma$  (AF700, Invitrogen) antibodies. After fixation with PBS 2% PFA, cells  
23 were acquired in a BD LSR Fortessa flow cytometer (Cytomics Platform, High Technology Unit,  
24 Vall d’Hebron Institut de Recerca).

25

#### 26 **Phenotyping and Intracellular Cytokine Staining in blood**

27 Freshly isolated PBMCs were labelled for CCR7 (PE-CF594, BD Biosciences) and CXCR3  
28 (BV650, BD Biosciences) for 30 min at 37°C. After washing with PBS, PBMCs were stimulated in  
29 a 96-well round-bottom plate for 16 to 18 hours at 37°C with 1µg/mL of SARS-CoV-2 peptides  
30 together with the same concentration of Brefeldin A, Monensin, α-CD28/CD49d and CD107a-PE-  
31 Cy5, as stated for the lung suspension above and published before<sup>1</sup>. For each patient, a negative  
32 control and a positive control were also included. After stimulation, cells were washed twice with  
33 PBS and stained with Aqua LIVE/DEAD fixable dead cell stain kit (Invitrogen). Cell surface  
34 antibody staining included anti-CD3 (Per-CP), anti-CD4 (BV605) and anti-CD56 (FITC) (all from

1 BD Biosciences). Cells were subsequently fixed and permeabilized using the Cytotfix/Cytoperm  
2 kit (BD Biosciences) and stained with anti-Caspase-3 (AF647, BD Biosciences), anti-Bcl-2  
3 (BV421, Biolegend), anti-IL-4 (PE-Cy7, eBioscience), anti-IL-10 (PE, BD Biosciences) and anti-  
4 IFN $\gamma$  (AF700, Invitrogen) for 30 mins. Cells were then fixed with PBS 2% PFA and acquired in a  
5 BD LSR Fortessa flow cytometer.

6

### 7 **SARS-CoV-2 serology**

8 The serological status of patients included in this study was determined in serum samples using  
9 two commercial chemiluminescence immunoassays (CLIA) targeting specific SARS-CoV-2  
10 antibodies: (1) Elecsys Anti-SARS-CoV-2 (Roche Diagnostics, Mannheim, Germany) was  
11 performed on the Cobas 8800 system (Roche Diagnostics, Basel, Switzerland) for the  
12 determination of total antibodies (including IgG, IgM, and IgA) against nucleocapsid (N) SARS-  
13 CoV-2 protein; and (2) Liaison SARS-CoV-2 TrimericS IgG (DiaSorin, Stillwater, MN) was  
14 performed on the LIAISON XL Analyzer (DiaSorin, Saluggia, Italy) for the determination of IgG  
15 antibodies against the spike (S) glycoprotein.

16

### 17 **Pseudovirus neutralization assay**

18 The spike of the Omicron SARS-CoV-2 was generated (GeneArt Gene Synthesis, ThermoFisher  
19 Scientific) from the plasmid containing the D614G mutation with a deletion of 19 amino acids,  
20 which was modified to include the mutations specific for this VOC (A67V,  $\Delta$ 69-70, T95I,  
21 G142D/ $\Delta$ 143-145,  $\Delta$ 211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K,  
22 G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y,  
23 N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) (kindly provided by Drs. J.  
24 Blanco and B. Trinite). Pseudotyped viral stocks of VSV\* $\Delta$ G(Luc)-S were generated following the  
25 protocol described in<sup>29</sup>. Briefly, 293T cells were transfected with 3 $\mu$ g of the omicron plasmid  
26 (pcDNA3.1 omicron). Next day, cells were infected with a VSV-G-Luc virus (MOI=1) for 2h and  
27 washed twice with warm PBS. To neutralize contaminating VSV\* $\Delta$ G(Luc)-G particles cells were  
28 incubated overnight in media containing 10% of the supernatant from the I1 hybridoma (ATCC  
29 CRL-2700), containing anti-VSV-G antibodies. Next day, viral particles were harvested and  
30 titrated in VeroE6 cells by enzyme luminescence assay (Britelite plus kit; PerkinElmer). For the  
31 neutralization assays, VeroE6 cells were seeded in 96-well white, flat-bottom plates (Thermo  
32 Scientific) at 30,000 cells/well. Plasma samples were heat-inactivated and diluted four-fold  
33 towards a concentration of 1/32 of the initial sample. Diluted plasma samples were then incubated  
34 with pseudotyped virus (VSV\* $\Delta$ G(Luc)-S<sup>omicron</sup>) with titers of approximately  $1 \times 10^6 - 5 \times 10^5$  RLU/ml

1 of luciferase activity - in a 96 well-plate flat bottom for 1 hour at 37°C, 5% CO<sub>2</sub>. Next, 30,000 Vero  
2 E6 cells were added to each well and incubated at 37°C, 5% CO<sub>2</sub> for 20-24 hours. Then, viral  
3 entry was measured by the expression of luciferase. Cells were incubated with Britelite plus  
4 reagent (Britelite plus kit; PerkinElmer) and then transferred to an opaque black plate.  
5 Luminescence was immediately recorded by a luminescence plate reader (LUMIstar Omega).  
6 Viral neutralization was calculated as the reciprocal plasma dilution (ID<sub>50</sub>) resulting in a 50%  
7 reduction in relative light units. If no neutralization was observed, an arbitrary titer value of 16 (half  
8 of the limit of detection [LOD]) was reported.

9

## 10 **Statistical analyses**

11 Flow cytometry data was analyzed using FlowJo v10.7.1 software (TreeStar). Data and statistical  
12 analyses were performed using Prism 8.0 (GraphPad Software, La Jolla, CA, USA). Data shown  
13 in bar graphs were expressed as median and Interquartile range (IQR), unless stated otherwise.  
14 Correlation analyses were performed using non-parametric Spearman rank correlation. Kruskal-  
15 Wallis rank-sum test with Dunn's post-hoc test was used for multiple comparisons. Friedmann  
16 test with Dunn's post-hoc test was applied for paired comparisons. A *P* value <0.05 was  
17 considered statistically significant. Antigen-specific T-cell data was calculated as the net  
18 frequency, where the individual percentage of expression for a given molecule in the control  
19 condition (vehicle) was subtracted from the corresponding SARS-CoV-2-peptide stimulated  
20 conditions.

21

## 22 **ACKNOWLEDGMENTS**

23 We would like to thank all the patients who participated in the study and Drs. Julià Blanco and  
24 Benjamin Trinite for providing the plasmid encoding the omicron spike. This work was supported  
25 by grants from Fundació La Marató TV3 (201814-10 FMTV3 and 202112-30 FMTV3), from the  
26 Health department of the Government of Catalonia (DGRIS 1\_5), and the Spanish AIDS network  
27 Red Temática Cooperativa de Investigación en SIDA (RD16/0025/0007). M.J.B is supported by  
28 the Miguel Servet program funded by the Spanish Health Institute Carlos III (CP17/00179). The  
29 funders had no role in study design, data collection and analysis, the decision to publish, or  
30 preparation of the manuscript.

31

## 32 **AUTHOR CONTRIBUTIONS**

33 Conceptualization, M.G.; Patient Recruitment and Sample Collection, J.R., V.F.; Methodology,  
34 DKJ.P., SG.K., A.G.R., J.R-C, C.M., J.E.; Investigation, DKJ.P., SG.K., A.G.R., J.E.; Formal

1 Analysis, DKJ.P., A.G.R., M.J.B. and M.G.; Writing-Original Draft, DKJ.P. and M.G; Writing-  
2 Review & Editing, all authors; Funding Acquisition, M.G.; Supervision, M.G.

3

#### 4 **DECLARATION OF CONFLICT OF INTEREST**

5 The authors declare no competing interest.

6

#### **DATA AVAILABILITY**

The authors declare that the data supporting the findings of this study are available within the paper and its supplementary information files.

#### **REFERENCES**

- 7 1. Grau-Exposito J, Sanchez-Gaona N, Massana N, Suppi M, Astorga-Gamaza A, Perea D, *et al.* Peripheral  
8 and lung resident memory T cell responses against SARS-CoV-2. *Nature communications* 2021, **12**(1):  
9 3010.
- 10 2. Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, *et al.* Neutralising antibody titres as  
11 predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *The*  
12 *Lancet Microbe* 2022, **3**(1): e52-e61.
- 13 3. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, *et al.* SARS-CoV-2 variants of  
14 concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees.  
15 *Science immunology* 2021, **6**(59).
- 16 4. Keeton R, Tincho MB, Ngomti A, Baguma R, Benede N, Suzuki A, *et al.* T cell responses to SARS-CoV-2  
17 spike cross-recognize Omicron. *Nature* 2022, **603**(7901): 488-492.
- 18 5. Moss P. The T cell immune response against SARS-CoV-2. *Nat Immunol* 2022, **23**(2): 186-193.
- 19 6. Kundu R, Narean JS, Wang L, Fenn J, Pillay T, Fernandez ND, *et al.* Cross-reactive memory T cells  
20 associate with protection against SARS-CoV-2 infection in COVID-19 contacts. *Nature communications*  
21 2022, **13**(1): 80.
- 22 7. Niessl J, Sekine T, Buggert M. T cell immunity to SARS-CoV-2. *Seminars in immunology* 2021, **55**: 101505.
- 23 8. Jung JH, Rha MS, Sa M, Choi HK, Jeon JH, Seok H, *et al.* SARS-CoV-2-specific T cell memory is sustained  
24 in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T  
25 cells. *Nature communications* 2021, **12**(1): 4043.
- 26 9. Szabo PA, Dogra P, Gray JI, Wells SB, Connors TJ, Weisberg SP, *et al.* Longitudinal profiling of respiratory  
27 and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19.  
28 *Immunity* 2021, **54**(4): 797-814 e796.
- 29 10. Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, *et al.* mRNA vaccines induce  
30 durable immune memory to SARS-CoV-2 and variants of concern. *Science* 2021, **374**(6572): abm0829.
- 31 11. Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Galvez RI, *et al.* Humoral and cellular immune  
32 memory to four COVID-19 vaccines. *bioRxiv : the preprint server for biology* 2022.
- 33 12. Ortega N, Ribes M, Vidal M, Rubio R, Aguilar R, Williams S, *et al.* Seven-month kinetics of SARS-CoV-2  
34 antibodies and role of pre-existing antibodies to human coronaviruses. *Nature communications* 2021, **12**(1):  
35 4740.
- 36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

- 1 13. Minervina AA, Pogorelyy MV, Kirk AM, Crawford JC, Allen EK, Chou CH, *et al.* SARS-CoV-2 antigen  
2 exposure history shapes phenotypes and specificity of memory CD8 T cells. *medRxiv : the preprint server*  
3 *for health sciences* 2022.
- 4 14. Sheikh-Mohamed S, Isho B, Chao GYC, Zuo M, Cohen C, Lustig Y, *et al.* Systemic and mucosal IgA  
5 responses are variably induced in response to SARS-CoV-2 mRNA vaccination and are associated with  
6 protection against subsequent infection. *Mucosal immunology* 2022.
- 7 15. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, *et al.* A Single-Dose Intranasal ChAd  
8 Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* 2020, **183**(1): 169-184  
9 e113.
- 10 16. Channappanavar R, Zhao J, Perlman S. T cell-mediated immune response to respiratory coronaviruses.  
11 *Immunologic research* 2014, **59**(1-3): 118-128.
- 12 17. Le Bert N, Clapham HE, Tan AT, Chia WN, Tham CYL, Lim JM, *et al.* Highly functional virus-specific cellular  
13 immune response in asymptomatic SARS-CoV-2 infection. *The Journal of experimental medicine* 2021,  
14 **218**(5).
- 15 18. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, *et al.* Targets of T Cell Responses  
16 to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* 2020,  
17 **181**(7): 1489-1501 e1415.
- 18 19. Taus E, Hofmann C, Ibarondo FJ, Hausner MA, Fulcher JA, Krogstad P, *et al.* Dominant CD8(+) T Cell  
19 Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. *Front*  
20 *Immunol* 2022, **13**: 835830.
- 21 20. Demaret J, Lefevre G, Vuotto F, Trauet J, Duhamel A, Labreuche J, *et al.* Severe SARS-CoV-2 patients  
22 develop a higher specific T-cell response. *Clinical & translational immunology* 2020, **9**(12): e1217.
- 23 21. Thieme CJ, Anft M, Paniskaki K, Blazquez-Navarro A, Doevelaar A, Seibert FS, *et al.* Robust T Cell  
24 Response Toward Spike, Membrane, and Nucleocapsid SARS-CoV-2 Proteins Is Not Associated with  
25 Recovery in Critical COVID-19 Patients. *Cell reports Medicine* 2020, **1**(6): 100092.
- 26 22. Poon MML, Byington E, Meng W, Kubota M, Matsumoto R, Grifoni A, *et al.* Heterogeneity of human anti-  
27 viral immunity shaped by virus, tissue, age, and sex. *Cell reports* 2021, **37**(9): 110071.
- 28 23. Romero-Olmedo AJ, Schulz AR, Hochstatter S, Das Gupta D, Virta I, Hirseland H, *et al.* Induction of robust  
29 cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously  
30 unresponsive older adults. *Nature microbiology* 2022, **7**(2): 195-199.
- 31 24. Matchett WE, Joag V, Stolley JM, Shepherd FK, Quarnstrom CF, Mickelson CK, *et al.* Cutting Edge:  
32 Nucleocapsid Vaccine Elicits Spike-Independent SARS-CoV-2 Protective Immunity. *Journal of immunology*  
33 2021, **207**(2): 376-379.
- 34 25. Peng Y, Felce SL, Dong D, Penkava F, Mentzer AJ, Yao X, *et al.* An immunodominant NP105-113-B\*07:02  
35 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. *Nat*  
36 *Immunol* 2022, **23**(1): 50-61.
- 37 26. Mazzoni A, Di Lauria N, Maggi L, Salvati L, Vanni A, Capone M, *et al.* First-dose mRNA vaccination is  
38 sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-  
39 19. *The Journal of clinical investigation* 2021, **131**(12).
- 40 27. Skelly DT, Harding AC, Gilbert-Jaramillo J, Knight ML, Longet S, Brown A, *et al.* Two doses of SARS-CoV-2  
41 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. *Nature*  
42 *communications* 2021, **12**(1): 5061.
- 43 28. Mao T, Israelow B, Suberi A, Zhou L, Reschke M, Pena-Hernandez MA, *et al.* Unadjuvanted intranasal spike  
44 vaccine booster elicits robust protective mucosal immunity against sarbecoviruses. *bioRxiv : the preprint*  
45 *server for biology* 2022.

- 1 29. Grau-Exposito J, Perea D, Suppi M, Massana N, Vergara A, Soler MJ, *et al.* Evaluation of SARS-CoV-2  
2 entry, inflammation and new therapeutics in human lung tissue cells. *PLoS pathogens* 2022, **18**(1):  
3 e1010171.  
4

5



## FIGURE LEGENDS

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

**Fig. 1. SARS-CoV-2-specific T-cell responses in peripheral blood from convalescent and vaccinated patients.** (a) Representative flow-cytometry plots showing CD4<sup>+</sup> T cells expressing CD107a and IFN $\gamma$  after exposure of whole PBMCs to S-peptide pools or left unstimulated for each of the four groups included in this study (complete gating strategy is shown in Extended Data Fig. 2a). (b) Comparison of the net frequency (background subtracted) of IFN $\gamma$ <sup>+</sup> cells within CD4<sup>+</sup> (upper) and CD8<sup>+</sup> (lower) T-cell subsets after stimulation of PBMCs with any of the three viral peptide pools (membrane (M), nucleocapsid (N) and spike (S) peptides). Data are shown as median  $\pm$  IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). Statistical significance was determined by Kruskal-Wallis test (with Dunn's post-test).

**Fig. 2. SARS-CoV-2-specific lung T-cell responses from convalescent and vaccinated patients and comparison between tissue compartments.** (a) Representative flow-cytometry plots showing CD4<sup>+</sup> T cells expressing CD107a and IFN $\gamma$  after exposure of single-cell suspensions of lung tissue to S-peptide pools or left unstimulated for each of the four groups included in this study (complete gating strategy is shown in Extended Data Fig. 2b). (b) Comparison of the net frequency (background subtracted) of IFN $\gamma$ <sup>+</sup> cells within CD4<sup>+</sup> (upper) and CD8<sup>+</sup> (lower) T-cell subsets after exposure of lung single-cell suspensions to any of the three viral peptide pools (membrane (M), nucleocapsid (N) and spike (S) peptides). (c) Comparison of the net frequency of IFN $\gamma$ <sup>+</sup> cells within CD4<sup>+</sup> (left) and CD8<sup>+</sup> (right) T-cell subsets in paired blood and lung samples of each group after exposure to S-peptide pools. Data in bar graphs are shown as median  $\pm$  IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). Statistical significance was determined by (b) Kruskal-Wallis test (with Dunn's post-test) or (c) Friedmann test (with Dunn's post-test).

**Fig. 3. Frequency of Spike-specific T<sub>RM</sub> cells in the lung.** (a) Representative flow-cytometry plots showing three subsets of CD4<sup>+</sup> T cells present in the lung: CD69<sup>-</sup> non-T<sub>RM</sub>, CD69<sup>+</sup> T<sub>RM</sub>, and CD69<sup>+</sup>CD103<sup>+</sup> T<sub>RM</sub> cells expressing CD107a and IFN $\gamma$  after exposure of single-cell suspensions of lung tissue to S-peptide pools or left unstimulated for an Inf and a Vx2 patients. (b) Comparison of the net frequency of S-specific IFN $\gamma$ <sup>+</sup> cells within the three (non-) T<sub>RM</sub> cell subsets present in

1 the lung for each group. Data in bar graphs are shown as median  $\pm$  IQR, where each dot  
2 represents an individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=8;  
3 Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=4). Statistical significance was  
4 determined by Friedmann test (with Dunn's post-test) for the difference between the cellular  
5 subsets within each patient group.

6

7 **Fig. 4. Overall functional T-cell response of lung and blood compartments. (a, b)** Donut  
8 charts displaying the net contribution of each functional marker (IFN $\gamma$ , CD107a, IL-4, and IL-10)  
9 to the overall S-specific CD4<sup>+</sup> (a) and CD8<sup>+</sup> (b) T-cell response within the lung resident and non-  
10 resident T-cell subsets and in peripheral blood for each of the individual patient groups. Data  
11 represent the mean value of the net frequency of each function within the patient group, including  
12 both responders and non-responders. The frequency shown inside each donut chart represents  
13 the accumulated mean response of all functions. Bar charts on the right show the mean of the  
14 total frequency considering all functions per group (mean  $\pm$  SD). Statistical significance was  
15 determined by Kruskal-Wallis test (with Dunn's post-test) for the difference between each group.  
16 \*  $P < 0.05$ .

17

18 **Fig. 5. Polyfunctional CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses in blood and lung of convalescent**  
19 **and vaccinated patients. (a, b)** Comparison of the net frequency of polyfunctional CD107a<sup>+</sup>  
20 IFN $\gamma$ <sup>+</sup> cells within CD4<sup>+</sup> and CD8<sup>+</sup> T-cell subsets for each of the four groups after exposure of  
21 PBMCs (a) or single-cell suspensions of lung tissue (b) to any of the three viral peptide pools  
22 (membrane (M), nucleocapsid (N) and spike (S) peptides). Data in bar graphs are shown as  
23 median  $\pm$  IQR, where each dot represents an individual patient for each group (Ctrl, control, n=5;  
24 Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3, vaccine 3 doses, n=5).  
25 Statistical significance was determined by was determined using Kruskal-Wallis test (with Dunn's  
26 post-test).

27

28

29

30

31

32

33

34

## 1 EXTENDED DATA LEGENDS

2

3 **Extended Data Fig. 1. Correlation between SARS-CoV-2-specific antibodies, neutralizing**  
4 **capacity, age, and sampling time.** Graphs show the relationship between: (a) S-specific IgG  
5 antibodies (AU/mL) in plasma and SARS-CoV-2 neutralization titer for each group (Inf,  
6 convalescent infected, n=7; Vx2, vaccine 2 doses, n=6 and Vx3, vaccine 3 doses, n=4); (b, c)  
7 SARS-CoV-2 neutralization titer and age of Inf patients (b) and Vx2 patients (c); (d, e) S-specific  
8 IgG antibodies (AU/mL) and age of Inf patients (d) and Vx2 patients (e); (f) S-specific IgG  
9 antibodies (AU/mL) in all groups and day of sampling after infection or vaccination; and (e) N-  
10 specific Ig antibodies (index) in Inf patients and day of sampling after infection. Correlations ( $r$  and  
11  $P$  values) were assessed by Spearman test.

12

13 **Extended Data Fig. 2. Gating strategy for the analysis of T cells present in peripheral blood**  
14 **and lung tissue.** (a, b) Representative flow-cytometry plots showing the gating strategy towards  
15 the identification of CD4<sup>+</sup> and CD8<sup>+</sup> T cells within PMBC (a) and lung tissue (b) samples. CD4<sup>+</sup>  
16 and CD8<sup>+</sup> T-cell subsets in PBMCs were identified by gating of time (to exclude disturbances in  
17 flow measurements), followed by gating of total lymphocytes, single cells, and live cells. CD4<sup>+</sup>  
18 and CD8<sup>+</sup> T-cell subsets in lung tissue were identified by gating of time, live CD45<sup>+</sup> cells, single  
19 cells, and lymphocytes.

20

21 **Extended Data Fig. 3. Spike-specific T-cell responses (CD107a, IL-4, IL-10) in peripheral**  
22 **blood from convalescent and vaccinated patients.** Comparison of the net frequency of  
23 CD107a<sup>+</sup> (left), IL-4<sup>+</sup> (middle), and IL-10<sup>+</sup> (right) cells within CD4<sup>+</sup> (upper) and CD8<sup>+</sup> (lower) T-cell  
24 subsets for each of the four groups after exposure of PBMCs to S-peptide pools. Data in bar  
25 graphs are shown as median  $\pm$  IQR, where each dot represents an individual patient for each  
26 group (Ctrl, control, n=5; Inf, convalescent infected, n=9; Vx2, vaccine 2 doses, n=7 and Vx3,  
27 vaccine 3 doses, n=5). Statistical significance was determined by Kruskal-Wallis test (with Dunn's  
28 post-test).

29

30 **Extended Data Fig. 4. SARS-CoV-2-specific T-cell responses (CD107a, IL-4, IL-10) in the**  
31 **lung from convalescent and vaccinated patients.** (a) Comparison of the net frequency of  
32 CD107a<sup>+</sup> (left), IL-4<sup>+</sup> (middle), and IL-10<sup>+</sup> (right) cells within CD4<sup>+</sup> (upper) and CD8<sup>+</sup> (lower) T-cell  
33 subsets for each of the four groups after exposure of single-cell suspensions of lung tissue to S-  
34 peptide pools. Data in bar graphs are shown as median  $\pm$  IQR, where each dot represents an

1 individual patient for each group (Ctrl, control, n=5; Inf, convalescent infected, n=9; Vx2, vaccine  
2 2 doses, n=7 and Vx3, vaccine 3 doses, n=5). Statistical significance was determined by Kruskal-  
3 Wallis test (with Dunn's post-test). (b) Correlation between the net frequency of S-specific  
4 CD107a<sup>+</sup> cells of CD4<sup>+</sup> (left) and CD8<sup>+</sup> (right) T cells in the lung and age (Inf group). Correlations  
5 (*r* and *P* values) were assessed by Spearman test.

6  
7 **Extended Data Fig. 5. Comparison of the frequency of S-peptide specific CD4<sup>+</sup> and CD8<sup>+</sup> T**  
8 **cells between lung and blood.** (a-c) Graphs show the individual patient net frequency of  
9 CD107a<sup>+</sup> (a), IL-4<sup>+</sup> (b), and IL-10<sup>+</sup> (c) cells within CD4<sup>+</sup> (left) and CD8<sup>+</sup> (right) T-cell subsets of  
10 paired blood and lung samples that were exposed to S-peptide pools. Statistical significance was  
11 determined using Friedmann test (with Dunn's post-test) for the difference between blood and  
12 lung samples within each patient group.

13  
14 **Extended Data Fig. 6. The response of CD4<sup>+</sup> and CD8<sup>+</sup> (non-) T<sub>RM</sub> cells against M and N**  
15 **peptide pools.** (a, b) Comparison of the net frequency of IFN $\gamma$ <sup>+</sup> cells within three T<sub>RM</sub>-cell subsets  
16 of CD4<sup>+</sup> (left) and CD8<sup>+</sup> (right) T cells present in the lung: CD69<sup>-</sup> non-T<sub>RM</sub>, CD69<sup>+</sup> T<sub>RM</sub>, and  
17 CD69<sup>+</sup>CD103<sup>+</sup> T<sub>RM</sub> cells for each group after exposure to (a) M- and (b) N-peptide pools. Data in  
18 bar graphs are shown as median  $\pm$  IQR, where each dot represents an individual patient for each  
19 group (Ctrl, control, n=5; Inf, convalescent infected, n=8; Vx2, vaccine 2 doses, n=7 and Vx3,  
20 vaccine 3 doses, n=4). Statistical significance was determined using Friedmann test (with Dunn's  
21 post-test) for the difference between the cellular subsets within each patient group. (c) Correlation  
22 between the net frequency of lung S-specific IFN $\gamma$ <sup>+</sup> cells within the CD8<sup>+</sup> CD69<sup>+</sup> CD103<sup>+</sup> T<sub>RM</sub>  
23 subset and days since confirmed infection and sampling (Inf group). (d) Correlation between the  
24 net frequency of S-specific CD107a<sup>+</sup> CD8<sup>+</sup> CD69<sup>+</sup> CD103<sup>+</sup> T<sub>RM</sub> cells or CD8<sup>+</sup> CD69<sup>+</sup> T<sub>RM</sub> cells and  
25 age (Inf group). Correlations (*r* and *P* values) were assessed by Spearman test.

26  
27 **Extended Data Fig. 7. Frequency of polyfunctional T-cell responses against spike with a**  
28 **tissue-resident phenotype in the lung.** Comparison of the net frequency of S-specific  
29 polyfunctional CD107a<sup>+</sup> IFN $\gamma$ <sup>+</sup> cells within lung CD4<sup>+</sup> (upper) and CD8<sup>+</sup> (lower) (non-) tissue-  
30 resident cell subsets (CD69<sup>-</sup> non-T<sub>RM</sub>, CD69<sup>+</sup> T<sub>RM</sub>, and CD69<sup>+</sup>CD103<sup>+</sup> T<sub>RM</sub> cells) for each of the  
31 four patient groups after exposure of single-cell lung suspensions to S-peptide pools. Data in bar  
32 graphs are shown as median  $\pm$  IQR, where each dot represents an individual patient for each  
33 group (Ctrl, control, n=5; Inf, convalescent infected, n=8; Vx2, vaccine 2 doses, n=7 and Vx3,

1 vaccine 3 doses, n=4). Statistical significance was determined by Kruskal-Wallis test (with Dunn's  
2 post-test) for the difference between the groups.

3  
4 **Extended Data Fig. 8. T-cell responses for patient #174.** (a) Timeline for patient 174, indicating  
5 vaccination against SARS-CoV-2, infection with SARS-CoV-2, and acquisition of blood and lung  
6 samples. (b) Donut charts displaying the net contribution of each functional marker (IFN $\gamma$ ,  
7 CD107a, IL-4, IL-10, or no response) to the M-, N-, and S-specific CD4 $^{+}$  and CD8 $^{+}$  T-cell response  
8 within the lung resident and non-resident T-cell subsets and in peripheral blood for patient 174.  
9 The frequency shown inside each donut chart represents the accumulated mean response of all  
10 functions. (c) Flow-cytometry plots of patient 174 showing CD4 $^{+}$  (upper) and CD8 $^{+}$  (lower) T cells  
11 expressing CD107a and IFN $\gamma$  after exposure of lung single-cell suspensions (left) and PBMCs  
12 (right) to M-, N- and S-peptide pools or left unstimulated.

13  
14 **Extended Data Fig. 9. T-cell responses for patient #162, longitudinal samples.** (a) Timeline  
15 for patient 162 who was longitudinally sampled, first ~4 months after SARS-CoV-2 infection and  
16 then ~1 month after third dose mRNA-vaccination. (b, c) Donut charts displaying the net  
17 contribution of each functional marker (IFN $\gamma$ , CD107a, IL-4, IL-10, or no response) to the M-, N-,  
18 and S-specific CD4 $^{+}$  and CD8 $^{+}$  T-cell response within the lung resident and non-resident T-cell  
19 subsets and in peripheral blood for patient 162 in the first sample (b) and second sample (c). The  
20 frequency shown inside the donut chart represents the accumulated mean response of all  
21 functions.

22  
23 **Extended Data Fig. 10. Longitudinal patterns of SARS-CoV-2-specific T-cell responses in**  
24 **lung and blood for patient #162.** (a, b) Flow-cytometry plots showing longitudinal data (left, after  
25 infection, sample 1; right, after third-dose vaccination, sample 2) of patient 162 showing CD4 $^{+}$   
26 (top) and CD8 $^{+}$  (bottom) T cells expressing CD107a and IFN $\gamma$  after exposure of PBMCs (a) and  
27 lung cell suspension (b) to M-, N-, and S-peptide pools or left unstimulated (vehicle).

28

**Extended Table 1. Patient characteristics**

	<b>Control n=5</b>	<b>Infected n=9‡</b>	<b>Vx2 n=7‡</b>	<b>Vx3 n=5‡</b>	<b>P value between groups</b>
Age (Years), median [IQR]	<b>67</b> [66-74]	<b>69</b> [65-71]	<b>61</b> [58-70]	<b>72</b> [69-73]	0.6555 <sup>a</sup>
Female, n (%)	<b>1/5</b> (20%)	<b>1/9</b> (11%)	<b>4/7</b> (57%)	<b>3/5</b> (60%)	0.0875 <sup>b</sup>
Days after infection* or vaccination, median [IQR]	N/A	<b>304</b> [183-320]	<b>206</b> [184-234]	<b>52</b> [42-54]	<b>0.0006</b> <sup>a</sup>
Spike-specific IgG** (AU/mL), median [IQR] (AU/mL)	<b>&lt;1.85</b> [1.85-1.85]	<b>133.1</b> [89.04-228.46]	<b>225</b> [118.85-248.46]	<b>800</b> [716,35-800]	<b>0.0122</b> <sup>a</sup>
Total nucleocapsid-specific Ig** (Index), median [IQR]	<b>0.07</b> [0.07-0.08]	<b>135</b> [62.1-157.5]	<b>0.1</b> [0.07-0.11]	<b>0.1</b> [0.06-0.09]	<b>0.0001</b> <sup>a</sup>
Virus neutralization titer***, median [IQR]	<b>0</b> [0-0]	<b>40</b> [19-56]	<b>50</b> [46.25-471.5]	<b>138.5</b> [67.75-665.75]	0.0974 <sup>a</sup>
Patients with SARS-CoV-2 neutralization capacity, n (%)	<b>0/5</b> (0%)	<b>5/7</b> (71%)	<b>5/6</b> (83%)	<b>4/4</b> (100%)	0.4877 <sup>b</sup>
New infection after sampling, n (%)	<b>0/5</b> (0%)	<b>0/9</b> (0%)	<b>1/7</b> (14%)	<b>0/5</b> (0%)	0.3763 <sup>b</sup>

\* Confirmed by RT-PCR for SARS-CoV-2

\*\* Measured by anti-SARS-CoV-2 S and N immunoassay


\*\*\* Measured by SARS-CoV-2 neutralization assay

‡ Plasma samples were not available for every patient

N/A not available

<sup>a</sup> Kruskal-Wallis test with Dunn's post-test<sup>b</sup> Chi-square test

Figure 1



medRxiv preprint doi: <https://doi.org/10.1101/2022-05-25.22275300>; this version posted May 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).







Figure 2




medRxiv preprint doi: <https://doi.org/10.1101/2022.05.25.22275300>; this version posted May 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).






a



### S-specific CD4<sup>+</sup> T cells




### S-specific CD8<sup>+</sup> T cells

b









**a****Blood****b****Lung**

# Extended Figure 1




medRxiv preprint doi: <https://doi.org/10.1101/2022.05.25.22252900>; this version posted May 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).




# Extended Figure 2

**a**




medRxiv preprint doi: <https://doi.org/10.1101/2022.05.25.22275300>; this version posted May 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



**b**



# Extended Figure 3




# Extended Figure 4




# Extended Figure 5


a



b




c






# Extended Figure 6


a





b




c




d





# Extended Figure 7



# Extended Figure 8



medRxiv preprint doi: <https://doi.org/10.1101/2022.05.25.22275300>; this version posted May 26, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).





# Extended Figure 10

